BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Figure out How to Streamline Eco-friendliness in Your Volvo XC40 - 2Couch Styles of 2024: What's Moving
- 3Israeli media reports Iran attacking greater Tel Aviv region
- 4Becoming amazing at Systems administration: Individual and Expert Tips
- 5Space debris: will it take a catastrophe for nations to take the issue seriously?
- Famous Places to get-away for Americans
- Study reveals links between global food systems, obesity, and climate change
- What to know about new CDC deputy director who has been critical of COVID vaccines
- Figure out How to Augment Your Rooftop Substitution Speculation
- Understanding Various Sorts of Financial balances: An Extensive Outline
- Step in Style: A Survey of \Solace and Execution on the Track\ Running Shoes
- 'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- Fisherman Attacked by Great White Shark Says ‘My Left Foot Was in His Mouth’
- Mali and Canadian miner Barrick agree to resolve tax dispute, ending 2-year standoff
